This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CYAN Cyanotech (CYAN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsEarningsHeadlinesInsider TradesTrendsBuy This Stock About Cyanotech Stock (NASDAQ:CYAN) 30 days 90 days 365 days Advanced Chart Get Cyanotech alerts:Sign Up Key Stats Today's Range$0.32▼$0.3450-Day Range$2.83▼$3.2652-Week Range$2.37▼$6.29Volume10,600 shsAverage Volume3,483 shsMarket Capitalization$2.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.Read More… Receive CYAN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyanotech and its competitors with MarketBeat's FREE daily newsletter. Email Address CYAN Stock News HeadlinesCyanotech Corp (CYAN) Q3 2025 Earnings Call Highlights: Strong Sales Growth and Improved ...February 14, 2025 | finance.yahoo.comQ3 2025 Cyanotech Corp Earnings CallFebruary 13, 2025 | finance.yahoo.comSecure this "AI Fuel" Stock Before the Billionaires Buy It AllThe Washington Post says America is running out of a key material needed for AI—and without it, companies like NVIDIA could be forced to shut down. While billionaires like Buffett and Gates scramble to secure access, one under-the-radar firm has quietly locked up supply. Bloomberg even calls it a “monopoly.” And it’s still trading near $20.May 18, 2025 | Behind the Markets (Ad)Cyanotech Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2025February 11, 2025 | finanznachrichten.deSpirulina Beverages Market and Consumer Behaviour Analysis, 2025-2030 - Prolgae Spirulina Supplies, Cyanotech Corporation, FUL Foods, Sol-Ti, and Raw Juicery Lead the Projected $61 Million MarketJanuary 21, 2025 | globenewswire.comCyanotech Reports Financial Results for the Second Quarter and First Six Months of Fiscal 2025November 13, 2024 | finanznachrichten.deThe Microalgae Market to Reach $2.26 Billion by 2031--Exclusive Report by Meticulous Research®October 22, 2024 | finance.yahoo.comAstaxanthin Market to Reach $1.6 Billion, Globally, by 2033 at 8.1% CAGR: Allied Market ResearchOctober 9, 2024 | finance.yahoo.comSee More Headlines CYAN Stock Analysis - Frequently Asked Questions How were Cyanotech's earnings last quarter? Cyanotech Co. (NASDAQ:CYAN) issued its quarterly earnings data on Tuesday, November, 12th. The biotechnology company reported ($0.16) earnings per share for the quarter. The biotechnology company earned $5.85 million during the quarter. Cyanotech had a negative net margin of 19.50% and a negative trailing twelve-month return on equity of 44.71%. What other stocks do shareholders of Cyanotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cyanotech investors own include AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), Allena Pharmaceuticals (ALNA), Clarivate (CCC), Karyopharm Therapeutics (KPTI) and Madrigal Pharmaceuticals (MDGL). Company Calendar Last Earnings11/12/2024Today5/18/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medicinals & botanicals Sub-IndustryN/A Current SymbolNASDAQ:CYAN CIK768408 Webwww.cyanotech.com Phone(808) 326-1353Fax808-329-4533Employees95Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,270,000.00 Net Margins-19.50% Pretax Margin-19.48% Return on Equity-44.71% Return on Assets-19.12% Debt Debt-to-Equity Ratio0.11 Current Ratio1.06 Quick Ratio0.28 Sales & Book Value Annual Sales$23.07 million Price / Sales0.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book0.24Miscellaneous Outstanding Shares7,160,000Free Float5,074,000Market Cap$2.29 million OptionableNot Optionable Beta-0.11 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:CYAN) was last updated on 5/18/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWashington Is Broke—and Eyeing Your Savings NextWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowMusk has launched a bold new AI initiative—and while you can’t invest in it directly, one overlooked stock cou...Behind the Markets | Sponsored“Market Wizard” signals rare opportunityThe Fed Is Losing Control — What Comes Next Will Shock Traders The Fed is stuck — rising inflation and risi...Brownstone Research | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyanotech Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyanotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.